Bayesian Capital Management, LP Novavax Inc Transaction History

Bayesian Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.89 - $20.97 $98,028 - $528,444	25,200 New	25,200 $319,000
Q3 2023 Nov 14, 2023	BUY	$6.81 - $9.74 $375,912 - $537,648	55,200 Added 196.44%	83,300 $603,000
Q2 2023 Aug 14, 2023	BUY	$6.67 - $9.52 $187,427 - $267,512	28,100 New	28,100 $208,000
Q2 2022 Aug 15, 2022	SELL	$36.28 - $75.29 $508,246 - $1.05 Million	-14,009 Reduced 47.68%	15,374 $791,000
Q1 2022 May 16, 2022	BUY	$69.73 - $142.9 $2.05 Million - $4.2 Million	29,383 New	29,383 $2.16 Million
Q4 2021 Feb 14, 2022	SELL	$134.56 - $217.97 $652,077 - $1.06 Million	-4,846 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$177.8 - $270.58 $861,618 - $1.31 Million	4,846 New	4,846 $1.01 Million
Q4 2020 Feb 12, 2021	SELL	$78.74 - $139.5 $1.06 Million - $1.87 Million	-13,400 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$79.44 - $178.51 $1.06 Million - $2.39 Million	13,400 New	13,400 $1.45 Million

291

93.3M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $573M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.